Novonesis Q1 Organic Sales Rise 7%

Novonesis reported 7% organic sales growth in Q1, beating Jefferies' 6.2% consensus estimate.
Adjusted EBITDA increased to €423 million (margin 37.8%) while adjusted net profit rose 8% and free cash flow grew 9% to €74 million.
CEO Ester Baiget reaffirmed full‑year guidance of 5‑7% organic sales growth and 37‑38% EBITDA margin, citing 2030 targets.
Food & Health Biosolutions grew 9% organically, Planetary Health Biosolutions 5%; Developed Markets +8%, Emerging Markets +4% (incl. exits).